Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.

ABSTRACT:

Introduction

Community acquired pneumonia (CAP) is associated with high rates of morbidity and mortality, especially among the elderly. Antibiotic treatment for CAP in the elderly is particularly challenging for many reasons, including compliance issues, immunosuppression, polypharmacy and antimicrobial resistance. There are few available antibiotics that are able to address these concerns. Areas covered: After a systematic review of the current literature, we describe seven novel antibiotics that are currently in advanced stages of development (phase 3 and beyond) and show promise for the treatment of CAP in those over the age of 65. These antibiotics are: Solithromycin, Pristinamycin, Nemonaxacin, Lefamulin, Omadacycline, Ceftobiprole and Delafloxacin. Using a novel conceptual fr

SUBMITTER: Amalakuhan B 

PROVIDER: S-EPMC6092187 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature